FI80594B - Foerfarande foer framstaellning av en komposition som frigoers kontinuerligt polypeptid, poly(laktidkoglykolid)polymer och foerfarande foer dess framstaellning. - Google Patents

Foerfarande foer framstaellning av en komposition som frigoers kontinuerligt polypeptid, poly(laktidkoglykolid)polymer och foerfarande foer dess framstaellning. Download PDF

Info

Publication number
FI80594B
FI80594B FI820467A FI820467A FI80594B FI 80594 B FI80594 B FI 80594B FI 820467 A FI820467 A FI 820467A FI 820467 A FI820467 A FI 820467A FI 80594 B FI80594 B FI 80594B
Authority
FI
Finland
Prior art keywords
polypeptide
polylactide
polymer
release
lactic acid
Prior art date
Application number
FI820467A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI820467L (fi
Inventor
Francis Gowland Hutchinson
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10519727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI80594(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ici Plc filed Critical Ici Plc
Publication of FI820467L publication Critical patent/FI820467L/fi
Application granted granted Critical
Publication of FI80594B publication Critical patent/FI80594B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyethers (AREA)
FI820467A 1981-02-16 1982-02-12 Foerfarande foer framstaellning av en komposition som frigoers kontinuerligt polypeptid, poly(laktidkoglykolid)polymer och foerfarande foer dess framstaellning. FI80594B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8104734 1981-02-16
GB8104734 1981-02-16

Publications (2)

Publication Number Publication Date
FI820467L FI820467L (fi) 1982-08-17
FI80594B true FI80594B (fi) 1990-03-30

Family

ID=10519727

Family Applications (1)

Application Number Title Priority Date Filing Date
FI820467A FI80594B (fi) 1981-02-16 1982-02-12 Foerfarande foer framstaellning av en komposition som frigoers kontinuerligt polypeptid, poly(laktidkoglykolid)polymer och foerfarande foer dess framstaellning.

Country Status (20)

Country Link
US (2) US5004602A (forum.php)
EP (1) EP0058481B2 (forum.php)
JP (4) JPS57150609A (forum.php)
AT (1) ATE22535T1 (forum.php)
AU (3) AU560829B2 (forum.php)
CA (1) CA1169090A (forum.php)
DE (1) DE3273501D1 (forum.php)
DK (1) DK164845B (forum.php)
ES (1) ES509647A0 (forum.php)
FI (1) FI80594B (forum.php)
GR (1) GR76791B (forum.php)
HK (1) HK107890A (forum.php)
HU (2) HU186904B (forum.php)
IE (1) IE52535B1 (forum.php)
MY (1) MY101545A (forum.php)
NO (1) NO162103C (forum.php)
NZ (1) NZ199732A (forum.php)
PT (1) PT74434B (forum.php)
YU (1) YU44066B (forum.php)
ZA (1) ZA82565B (forum.php)

Families Citing this family (1046)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4637905A (en) * 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
US4652443A (en) * 1983-06-07 1987-03-24 Japan Atomic Energy Research Institute Slow-release composite and process for producing the same
CA1196864A (en) * 1983-06-10 1985-11-19 Mattheus F.A. Goosen Controlled release of injectable and implantable insulin compositions
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS6097918A (ja) * 1983-11-01 1985-05-31 Sumitomo Chem Co Ltd インタ−フエロン持続性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPS60181029A (ja) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
DE3434345A1 (de) * 1984-09-19 1986-03-27 Hoechst Ag, 6230 Frankfurt Verwendung von (alpha)-interferonen zur bekaempfung von durchfaellen
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
FR2581544B1 (fr) * 1985-05-10 1989-11-03 Univ Melbourne Procede pour provoquer une ovulation chez les juments et vehicule pharmaceutique associe
US5169633A (en) * 1985-07-29 1992-12-08 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5059422A (en) * 1985-07-29 1991-10-22 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5137874A (en) * 1985-07-29 1992-08-11 American Cyanamid Co. Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4643191A (en) * 1985-11-29 1987-02-17 Ethicon, Inc. Crystalline copolymers of p-dioxanone and lactide and surgical devices made therefrom
JPH0725688B2 (ja) * 1986-03-31 1995-03-22 住友製薬株式会社 Ｃｓｆ徐放性製剤
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
EP0248531A3 (en) * 1986-05-02 1988-09-28 Southern Research Institute Encapsulated nucleic acids
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4981696A (en) * 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
DE3701625A1 (de) * 1987-01-21 1988-08-04 Boehringer Ingelheim Kg Perorale arzneimittelzubereitung mit verzoegerter wirkstofffreigabe
DE3710175A1 (de) * 1987-02-12 1988-08-25 Hoechst Ag Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
AU606383B2 (en) * 1987-03-06 1991-02-07 Research Triangle Institute Polymer blends for selective biodegradability
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
GB8716324D0 (en) * 1987-07-10 1987-08-19 Sandoz Ltd Organic compounds
DE3845000C2 (de) * 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
US4866226A (en) * 1987-07-13 1989-09-12 Mitsubishi Denki Kabushiki Kaisha Multi-phase circuit breaker employing arc extinguishing apparatus
JPH0613602B2 (ja) * 1987-07-14 1994-02-23 三井東圧化学株式会社 ｄ▲ｌ▼−乳酸−グリコール酸共重合物の製造方法
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5212154A (en) * 1987-08-14 1993-05-18 Akzo N.V. Preparation for treating complications in diabetes
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US4902515A (en) * 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
FR2634770B1 (fr) * 1988-07-29 1990-10-05 Rhone Poulenc Chimie Composition polyester erodable contenant de l'iode pour le traitement des eaux
US5216050A (en) * 1988-08-08 1993-06-01 Biopak Technology, Ltd. Blends of polyactic acid
US5252642A (en) * 1989-03-01 1993-10-12 Biopak Technology, Ltd. Degradable impact modified polyactic acid
US5180765A (en) * 1988-08-08 1993-01-19 Biopak Technology, Ltd. Biodegradable packaging thermoplastics from lactides
US5502158A (en) * 1988-08-08 1996-03-26 Ecopol, Llc Degradable polymer composition
US6323307B1 (en) 1988-08-08 2001-11-27 Cargill Dow Polymers, Llc Degradation control of environmentally degradable disposable materials
US5444113A (en) * 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US5424346A (en) * 1988-08-08 1995-06-13 Ecopol, Llc Biodegradable replacement of crystal polystyrene
US5250584A (en) * 1988-08-31 1993-10-05 G-C Dental Industrial Corp. Periodontium-regenerative materials
US5633002A (en) * 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
US5247013A (en) * 1989-01-27 1993-09-21 Mitsui Toatsu Chemicals, Inc. Biocompatible polyester and production thereof
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ATE128362T1 (de) * 1989-03-10 1995-10-15 Endorecherche Inc Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
NZ234227A (en) * 1989-06-30 1991-08-27 Smithkline Beecham Corp Delayed release dosage form
ATE170753T1 (de) * 1989-07-07 1998-09-15 Endorecherche Inc Androgenderivate zur hemming der aktivität der sexualsteroide
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
JP3350048B2 (ja) * 1989-07-07 2002-11-25 アンドルシェルシュ・インコーポレイテッド アンドロゲン関連疾患の治療方法
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
CH679207A5 (forum.php) * 1989-07-28 1992-01-15 Debiopharm Sa
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
EP0423484B1 (de) * 1989-10-16 1993-11-03 PCD-Polymere Gesellschaft m.b.H. Pressling mit retardierter Wirkstofffreisetzung
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
WO1991017772A1 (en) * 1990-05-16 1991-11-28 Southern Research Institute Controlled release dopamine and its use to stimulate nerve fiber growth
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5620959A (en) * 1990-07-31 1997-04-15 Glaxo Wellcome Inc. Bombesin antagonists
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
US6353030B1 (en) 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
US5342557A (en) * 1990-11-27 1994-08-30 United States Surgical Corporation Process for preparing polymer particles
US7285531B1 (en) * 1991-04-10 2007-10-23 Acorda Therapeutics, Inc. Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
DE69311538D1 (de) * 1992-03-12 1997-07-17 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5429822A (en) * 1992-03-13 1995-07-04 Cambridge Scientific, Inc. Biodegradable bursting release system
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FI945457L (fi) * 1992-05-21 1995-01-16 Endorecherche Inc Testosteronin 5alfa-reduktaasiaktiviteetin inhibiittorit
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5281419A (en) * 1992-09-28 1994-01-25 Thomas Jefferson University Biodegradable drug delivery system for the prevention and treatment of osteomyelitis
AU670168B2 (en) * 1992-12-02 1996-07-04 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
UA61046C2 (en) 1992-12-07 2003-11-17 Takeda Chemical Industries Ltd Sustained-release preparation and method for its manufacture
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6221958B1 (en) 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
AU680650B2 (en) * 1993-01-06 1997-08-07 Ipsen Manufacturing Ireland Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
US5569467A (en) * 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5635216A (en) * 1993-12-16 1997-06-03 Eli Lilly And Company Microparticle compositions containing peptides, and methods for the preparation thereof
JPH08512056A (ja) * 1993-06-30 1996-12-17 ジェネンテク・インコーポレイテッド リポソームの製造法
EP0723402B1 (en) 1993-08-30 2010-08-18 Baylor College Of Medicine Senescent cell-derived inhibitors of dna synthesis
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US5496923A (en) * 1993-09-20 1996-03-05 Mitsui Toatsu Chemicals, Inc. Purification process of aliphatic polyester
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US20020193338A1 (en) * 1994-02-18 2002-12-19 Goldstein Steven A. In vivo gene transfer methods for wound healing
US6074840A (en) * 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
DE4406172C2 (de) * 1994-02-25 2003-10-02 Sanol Arznei Schwarz Gmbh Polyester
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6093697A (en) * 1994-11-07 2000-07-25 The University Of Virginia Patent Foundation Synthetic insulin mimetic substances
US5607686A (en) * 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
JPH11501027A (ja) * 1995-02-28 1999-01-26 イナファーマ，インコーポレイテッド 骨粗鬆症の処置のためのエルカトニン制御放出ミクロスフェア処方物
US5665702A (en) * 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US6479457B2 (en) 1995-06-06 2002-11-12 Kinerton Limited Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
FI970522A7 (fi) 1995-06-09 1997-04-07 Euro Celtique Sa Koostumukset ja menetelmät pidennetyn paikallisanestesian aikaansaamis eksi
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
ATE198607T1 (de) * 1995-08-29 2001-01-15 Kyowa Hakko Kogyo Kk Verfahren zur herstellung von polyhydroxycarbonsäure
WO1997007788A2 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
EP0823448A4 (en) * 1996-02-23 1998-08-12 Kyowa Hakko Kogyo Kk PROCESS FOR THE PREPARATION OF POLYHYDROXYCARBOXYLIC ACID
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
RU2165942C2 (ru) * 1996-04-23 2001-04-27 Кинертон Лимитид Биоразрушаемый сложный полиэфир и способ его получения (варианты)
IE960308A1 (en) 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5766877A (en) * 1996-05-10 1998-06-16 Amgen Inc. Genes encoding art, an agouti-related transcript
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
CA2260750C (en) 1996-06-24 2004-11-09 Euro-Celtique, S.A. Methods for providing safe local anesthesia
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5952455A (en) * 1996-10-11 1999-09-14 Kyowa Hakko Kogyo Co., Ltd. Process for producing polyhydroxycarboxylic acid
KR20050004269A (ko) 1996-10-25 2005-01-12 휴먼 게놈 사이언시즈, 인코포레이티드 뉴트로킨 알파
CA2219698C (en) 1996-10-31 2007-09-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US20020111603A1 (en) 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7235524B2 (en) * 1997-01-31 2007-06-26 Applied Research System Ars Holding N.V. Medicaments for initiating ovulation
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
AU7801998A (en) 1997-05-30 1998-12-30 Human Genome Sciences, Inc. 32 human secreted proteins
US6867181B1 (en) 1997-06-02 2005-03-15 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
CA2271750C (en) 1997-07-02 2004-04-27 Euro-Celtique, S.A. Prolonged anesthesia in joints and body spaces
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US6300127B1 (en) 1997-07-30 2001-10-09 Emory University Bone mineralization proteins, DNA, vectors, expression systems
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ES2333385T3 (es) 1997-09-17 2010-02-19 Human Genome Sciences, Inc. Proteina del tipo de interleuquina-17.
DE69811710T2 (de) 1997-11-07 2004-03-25 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
US6372880B1 (en) 1997-12-25 2002-04-16 Mitsui Chemicals, Inc. Copolymer and process for preparing the same
US5906979A (en) * 1998-01-27 1999-05-25 Insmed Pharmaceuticals, Inc. Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
EP1053020B1 (en) * 1998-01-29 2004-03-31 Poly-Med Inc. Absorbable microparticles
DK1051194T3 (da) 1998-01-29 2003-09-01 Kinerton Ltd Fremgangsmåde til fremstilling af absorberbare mikropartikler
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
PT2016951E (pt) 1998-03-17 2012-09-27 Genentech Inc Polipéptidos homólogos de vegf e de bmp1
EP1093457B8 (en) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AR020650A1 (es) * 1998-08-10 2002-05-22 Poly Med Inc Polimeros fosforilados y conjugados de los mismos
US20030007991A1 (en) * 1998-09-25 2003-01-09 Masters David B. Devices including protein matrix materials and methods of making and using thereof
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US7662409B2 (en) * 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
CN1200733C (zh) 1998-10-09 2005-05-11 拜奥根有限公司 阻断淋巴毒素β与其受体结合的物质在制备药物中的应用
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
DE69935614T2 (de) 1998-11-02 2007-11-29 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Lactongruppen tragende absorbierbare polymere
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6365173B1 (en) 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
US6303749B1 (en) 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
NZ583002A (en) 1999-02-03 2011-12-22 Amgen Inc Novel polypeptide B7RP-1 T cell ligand-receptor pair involved in immune response modulation
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
AU3556400A (en) 1999-03-17 2000-10-04 Novartis Ag Pharmaceutical compositions
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20030166561A1 (en) * 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
IL147029A0 (en) 1999-06-28 2002-08-14 Genentech Inc Method for making apo-2 ligand using divalent metal ions
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
PT1223990E (pt) 1999-10-15 2004-12-31 Fidia Advanced Biopolymers Srl Formulacoes de acido hialuronico para administracao de proteinas osteogenicas
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US6682754B2 (en) * 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
AU4935701A (en) * 2000-03-24 2001-10-08 Genentech Inc Use of insulin for the treatment of cartilagenous disorders
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
DK2236152T3 (da) 2000-04-12 2014-07-07 Novozymes Biopharma Dk As Albuminfusionsproteiner
IL153058A0 (en) * 2000-05-24 2003-06-24 Jordan Loyal Holtzman Agents and methods for increasing brain chaperonin levels
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2413673C (en) 2000-06-28 2018-01-09 Amgen Inc. Thymic stromal lymphopoietin receptor molecules and uses thereof
DE60118575T3 (de) * 2000-08-07 2011-05-19 Takeda Pharmaceutical Co. Ltd. Milchsäurepolymer und verfahren zu dessen herstellung
US6362308B1 (en) 2000-08-10 2002-03-26 Alkermes Controlled Therapeutics Inc. Ii Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
AU2001289019B2 (en) 2000-09-14 2006-07-27 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
CA2423431A1 (en) * 2000-10-06 2002-04-11 Durect Corporation Devices and methods for management of inflammation
DE10055742B4 (de) 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
JP2006500115A (ja) 2000-11-16 2006-01-05 マイクロスフエリツクス・エル・エル・シー 密封小線源治療用の可撓性および／または弾性シードまたはストランド
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
JP4236925B2 (ja) 2000-11-28 2009-03-11 アムジエン・インコーポレーテツド 免疫応答に関与する新規ポリペプチド
EP1404516A2 (en) 2000-12-13 2004-04-07 Purdue Research Foundation Microencapsulation of drugs by solvent exchange
EP1363602A4 (en) * 2001-01-25 2006-01-11 Euro Celtique Sa LOCAL ANESTHESIA, AND METHOD OF USE
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
GB0111628D0 (en) 2001-05-11 2001-07-04 Scancell Ltd Binding member
EP1399023B1 (en) 2001-06-01 2008-04-30 Wyeth COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENETIC PROTEINS& x9;
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
AU2002324447B2 (en) 2001-06-22 2006-06-29 Durect Corporation Zero-order prolonged release coaxial implants
EA021242B9 (ru) 2001-06-26 2015-11-30 Эмджен Фримонт Инк. Антитела к остеопротегерин лиганду (опгл)
TW200526267A (en) 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
EP1572887A4 (en) 2001-08-24 2008-12-24 Neuren Pharmaceuticals Ltd NERVE REGENERATING PEPTIDE AND METHOD FOR THEIR USE IN THE TREATMENT OF A BRAIN DAMAGE
ES2386346T3 (es) 2001-08-29 2012-08-17 Genentech, Inc. Ácidos nucleicos y polipéptidos Bv8 con actividad mitógena
CA2458261A1 (en) * 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use thereof
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
AU2002325711C1 (en) * 2001-09-14 2008-05-29 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
AU2002325710A1 (en) * 2001-09-18 2003-04-01 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
ATE419863T1 (de) 2001-09-24 2009-01-15 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
JP2005508162A (ja) 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド変異体とその使用法
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
ATE423571T1 (de) 2001-10-12 2009-03-15 Schering Corp Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
US7741282B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. ApO2 ligand/TRAIL formulations
NZ533434A (en) * 2001-11-14 2006-11-30 Alza Corp Thixotropic gel composition for injectable deposition
CU23043A1 (es) 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
EP2329839B1 (en) 2002-01-10 2015-09-16 Imperial Innovations Limited Modification of feeding behavior by GLP-1 and PYY
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
AU2003225895A1 (en) * 2002-03-19 2003-10-08 Purdue Research Foundation Microencapsulation using ultrasonic atomizers
JP4761710B2 (ja) 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
WO2003087163A1 (en) 2002-04-15 2003-10-23 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
US7732149B2 (en) 2002-04-26 2010-06-08 Chugai Seiyaku Kabushiki Kaisha Methods of screening agonistic antibodies
CA2483778A1 (en) 2002-04-29 2003-11-13 Gel-Del Technologies, Inc. Biomatrix structural containment and fixation systems and methods of use thereof
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
WO2004001009A2 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7368115B2 (en) * 2002-07-31 2008-05-06 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (PACAP)
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US8075585B2 (en) * 2002-08-29 2011-12-13 Stryker Corporation Device and method for treatment of a vascular defect
NZ605429A (en) 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
US7335743B2 (en) 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
ATE472556T1 (de) 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US8133507B2 (en) 2002-12-13 2012-03-13 Durect Corporation Oral drug delivery system
US7022481B2 (en) 2002-12-19 2006-04-04 Rosetta Inpharmatics Llc Methods of using glucan synthase pathway reporter genes to screen for antifungal compounds
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1440992A1 (fr) * 2003-01-21 2004-07-28 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Système catalytique de (co)polymérisation du lactide et du glycolide
NZ541595A (en) 2003-01-28 2008-08-29 Microbia Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
EP1601332A4 (en) 2003-03-07 2012-05-02 Verenium Corp HYDROLASES, NUCLEIC ACIDS ENCODING THEM, AND METHODS OF MAKING AND USING SAME
NZ541480A (en) 2003-03-12 2008-03-28 Genentech Inc Use of Bv8 and/or EG-VEGF to promote hematopoiesis
CA2518667C (en) 2003-03-14 2011-07-19 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
US20060076295A1 (en) * 2004-03-15 2006-04-13 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
US8067544B2 (en) 2003-03-19 2011-11-29 Curagen Corporation Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
PL2248899T3 (pl) 2003-03-19 2015-10-30 Biogen Ma Inc Białko wiążące receptor nogo
AU2004233851B2 (en) * 2003-04-25 2009-07-30 Novartis Vaccines And Diagnostics, Inc. Compositions comprising cationic microparticles and HCV E1E2 DNA and methods of use thereof
AU2004240630B2 (en) 2003-05-15 2010-10-07 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
US7375076B2 (en) 2003-05-20 2008-05-20 The Regents Of The University Of Michigan Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
BRPI0411852A (pt) 2003-06-27 2006-05-23 Abgenix Inc anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seu usos
JP5105874B2 (ja) 2003-07-18 2012-12-26 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合因子
EP2462923A3 (en) 2003-07-18 2012-08-29 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US8541051B2 (en) * 2003-08-14 2013-09-24 Halliburton Energy Services, Inc. On-the fly coating of acid-releasing degradable material onto a particulate
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
ES2373783T3 (es) 2003-09-12 2012-02-08 Tercica, Inc. Métodos para el tratamiento de la deficiencia de factor 1 de crecimiento similar a la insulina (igf-1).
UA88275C2 (ru) 2003-09-12 2009-10-12 Уайет Композиция, которая включает остеогенный белок и фосфат кальция, которая имеет форму твердого штифта, пригодного для внутрикостной инъекции, способ ее получения и применения
WO2005035754A1 (ja) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US7783006B2 (en) * 2003-10-10 2010-08-24 Xoft, Inc. Radiation treatment using x-ray source
US7309232B2 (en) * 2003-10-10 2007-12-18 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
US20050080313A1 (en) * 2003-10-10 2005-04-14 Stewart Daren L. Applicator for radiation treatment of a cavity
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
CN105820160B (zh) 2003-11-05 2019-02-12 萨可德生物科学公司 细胞粘着调节剂
EP2286791B1 (en) 2003-12-30 2014-03-26 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents
CN100534527C (zh) * 2003-12-30 2009-09-02 杜雷科特公司 用于控制释放优选为GnRH的活性剂的优选含有PEG和PLG的混合物的聚合植入物
EP1708734A4 (en) * 2004-01-07 2009-06-17 Trimeris Inc PEPTIDES DERIVED FROM HIV GP41 HR2 AND THEIR USE IN THERAPY TO INHIBIT THE TRANSMISSION OF HUMAN IMMUNODICIENCY VIRUS
WO2006069220A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US20070066525A1 (en) * 2004-02-04 2007-03-22 Lee John C Compositions and therapeutic methods using morphogenic proteins
US7846898B2 (en) 2004-02-13 2010-12-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
EP1729804A2 (en) 2004-03-19 2006-12-13 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
WO2005090564A1 (ja) 2004-03-19 2005-09-29 Genomidea Inc. 血管内皮増殖促進遺伝子
EP2332992A1 (en) 2004-03-23 2011-06-15 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
DK2447252T3 (da) 2004-05-23 2020-03-16 Hmi Medical Innovations Llc Theramuteinmodulatorer
AU2005247440B2 (en) 2004-05-25 2011-09-29 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
AU2005265163B2 (en) 2004-06-18 2009-10-01 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
WO2006009575A1 (en) 2004-06-22 2006-01-26 The Board Of Trustees Of The University Of Illinois METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
JP4960865B2 (ja) 2004-06-24 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄に関連する状態の処置
WO2006004774A2 (en) * 2004-06-28 2006-01-12 Stanford University Laulimalide analogues as therapeutic agents
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
JP5060293B2 (ja) 2004-08-03 2012-10-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経機能におけるｔａｊ
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
CA2575988C (en) * 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
RU2390355C2 (ru) 2004-08-12 2010-05-27 Квест Фармасьютикал Сёвисес Фармацевтические композиции для доставки с регулируемым высвобождением биологически активных соединений
WO2006023603A2 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
WO2006029406A2 (en) * 2004-09-09 2006-03-16 Stryker Corporation Methods for treating bone tumors using bone morphogenic proteins
PL2415484T3 (pl) 2004-09-17 2014-11-28 Durect Corp Kompozycja znieczulająca miejscowo o przedłużonym uwalnianiu zawierająca SAIB
CA2583061C (en) 2004-10-06 2015-02-17 Kwang Guan Tay Antibody production method
FR2876379B1 (fr) * 2004-10-08 2008-09-05 Isochem Sa Procede de polymerisation des o-carboxy anhydrides
JP4852773B2 (ja) 2004-10-15 2012-01-11 国立大学法人三重大学 肝再生・修復制御剤
CA2587903A1 (en) 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
DE602005027399D1 (de) 2004-12-20 2011-05-19 Amgen Fremont Inc Für humane matriptase spezifische bindungsproteine
CN101128483B (zh) 2004-12-21 2015-06-03 阿斯利康公司 血管生成素-2的抗体及其应用
SG158149A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1835885A1 (en) * 2004-12-23 2007-09-26 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of a gnrh
US20060153844A1 (en) * 2004-12-29 2006-07-13 Thomas Kundig Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
ES2395953T3 (es) 2005-01-26 2013-02-18 Amgen Fremont Inc. Anticuerpos frente a interleucina-1 beta
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
SI1876236T1 (sl) 2005-04-08 2014-11-28 Chugai Seiyaku Kabushiki Kaisha Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi
US20090054320A1 (en) * 2005-04-20 2009-02-26 Protemix Discovery Limited Vesiculins
EP1906929A2 (en) * 2005-04-25 2008-04-09 Amgen Inc. Biodegradable peptide sustained release compositions containing porogens
US7342048B2 (en) 2005-04-28 2008-03-11 Nipro Corporation Bioabsorbable pharmaceutical formulation
JP2008540571A (ja) 2005-05-12 2008-11-20 ウィスコンシン・アルムニ・リサーチ・ファウンデーション Ｐｉｎ１の遮断は活性化した免疫細胞によるサイトカイン産生を防ぐ
EP2444079B1 (en) 2005-05-17 2016-11-30 SARcode Bioscience Inc. Compositions and Methods for Treatment of Eye Disorders
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
EP3348639A3 (en) 2005-06-10 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Sc(fv)2 site-directed mutant
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
ES2439709T3 (es) 2005-06-21 2014-01-24 Xoma (Us) Llc Anticuerpos y fragmentos de los mismos que se unen a la IL-1beta
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof
ES2572177T3 (es) 2005-07-18 2016-05-30 Amgen Inc Anticuerpos neutralizantes anti-B7RP1 humanos
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20100004156A1 (en) 2005-07-27 2010-01-07 Shalesh Kaushal Small Compounds That Correct Protein Misfolding and Uses Thereof
EP2497781A1 (en) 2005-09-08 2012-09-12 Trustees Of Tufts College Stabilized GLP-1 analogs
US7534765B2 (en) * 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
CN101287464A (zh) 2005-09-29 2008-10-15 科学研究和应用咨询股份公司 用于刺激胃肠运动性的组合物和方法
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
JP5014143B2 (ja) 2005-10-14 2012-08-29 学校法人福岡大学 膵島移植における移植膵島障害抑制剤
JP5191235B2 (ja) 2005-10-21 2013-05-08 中外製薬株式会社 心疾患治療剤
NZ568705A (en) 2005-11-04 2012-07-27 Biogen Idec Inc Methods for promoting neurite outgrowth and survival of dopaminergic neurons
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
EP2548583A3 (en) 2005-11-10 2013-02-27 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
JP5398987B2 (ja) 2005-11-14 2014-01-29 セルミド リミテッド 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
AR057941A1 (es) 2005-11-25 2007-12-26 Univ Keio Agentes terapeuticos para el cancer de prostata
WO2007063421A2 (en) 2005-12-01 2007-06-07 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Compositions and methods relating to treatment of cancer and infectious diseases
JP5312039B2 (ja) 2005-12-02 2013-10-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄の関与する状態の処置
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
AU2006322887A1 (en) 2005-12-05 2007-06-14 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods for modulating an immune response
US8158588B2 (en) 2005-12-05 2012-04-17 Simon Delagrave Loop-variant PDZ domains as biotherapeutics, diagnostics and research reagents
ES2385054T3 (es) 2005-12-13 2012-07-17 Medimmune Limited Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas
ES2352205T3 (es) 2005-12-14 2011-02-16 Licentia Ltd. Usos de una proteína del factor neurotrófico.
NZ569787A (en) 2005-12-15 2011-07-29 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer
EP2918283B1 (en) 2005-12-30 2018-01-31 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
JPWO2007083644A1 (ja) 2006-01-17 2009-06-11 ディナベック株式会社 新規タンパク質発現系
KR20150017777A (ko) * 2006-01-18 2015-02-17 포시에이서 파마슈티컬스 인코포레이티드 안정성이 강화된 약학 조성물
EP1981902B1 (en) 2006-01-27 2015-07-29 Biogen MA Inc. Nogo receptor antagonists
US8771686B2 (en) 2006-01-27 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
CU23388B6 (es) * 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
WO2007092314A2 (en) 2006-02-02 2007-08-16 Verenium Corporation Esterases and related nucleic acids and methods
CN101415723B (zh) * 2006-02-02 2014-06-25 特里梅里斯公司 具有改良生物学特性的hiv融合抑制肽
EP2004212A4 (en) * 2006-03-17 2010-07-14 Stem Cell Therapeutics Corp CONTINUOUS DOSING SCHEMES FOR NEURAL STEM CELL PROLIFERATING AGENTS AND NEURAL STEM CELL DIFFERENTIATING AGENTS
EP1837014A1 (en) * 2006-03-21 2007-09-26 Hexal Ag Subcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
WO2007116962A1 (ja) 2006-04-07 2007-10-18 Osaka University 筋再生促進剤
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
AU2007254243B2 (en) 2006-05-17 2013-06-13 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
EP2035030A2 (en) 2006-05-17 2009-03-18 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
MX2008014732A (es) 2006-05-22 2009-04-07 Univ Columbia Sistemas y metodos de intercambio sin membrana microfluidica usando filtracion de corrientes de salida de fluidos de extraccion.
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
WO2007143121A2 (en) 2006-06-01 2007-12-13 President And Fellows Of Harvard College Purification of a bivalently active antibody using a non-chromatographic method
NZ572888A (en) 2006-06-08 2012-02-24 Chugai Pharmaceutical Co Ltd NR10/IL-31RA antagonist for preventing and treating inflammatory disease
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
EP2046435A4 (en) * 2006-07-13 2012-06-27 Medtronic Inc METHOD AND FORMULATIONS FOR OPTIMAL LOCAL ADMINISTRATION OF CELL THERAPY BY MEANS OF MINIMALLY INVASIVE PROCEDURES
TW200808351A (en) 2006-07-13 2008-02-16 Chugai Pharmaceutical Co Ltd Cell death-inducing agents
JP5175729B2 (ja) 2006-07-21 2013-04-03 中外製薬株式会社 腎疾患治療剤
JP5693004B2 (ja) 2006-07-28 2015-04-01 チルドレンズ メモリアル ホスピタル ヒト胚性幹細胞の微小環境を使用して腫瘍細胞の悪性度を抑制する方法
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
BRPI0718283A2 (pt) 2006-10-20 2013-11-12 Biogen Idec Inc Tratamento de distúrbios desmielinizantes
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2117521B1 (en) 2006-11-03 2012-06-27 Durect Corporation Transdermal delivery systems comprising bupivacaine
AU2007319359A1 (en) 2006-11-14 2008-05-22 Genentech, Inc. Modulators of neuronal regeneration
US7935796B2 (en) 2006-12-08 2011-05-03 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against ANGPTL3
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CA2671670C (en) 2006-12-18 2015-02-10 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
MX2009006709A (es) 2006-12-20 2009-07-02 Xoma Technology Ltd Tratamiento de enfermedades relacionadas con il-1beta.
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
DK2740744T3 (da) 2007-01-09 2018-04-23 Biogen Ma Inc Sp35-antistoffer og anvendelser deraf
TWI438208B (zh) 2007-01-23 2014-05-21 Chugai Pharmaceutical Co Ltd 抑制慢性排斥反應之藥劑
UA99452C2 (ru) 2007-02-02 2012-08-27 Байоджэн Айдэк Ма Инк. Способ стимулирования миелинизации и дифференцирования олигодендроцитов путем применения семафорина 6a
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
EP2139526A4 (en) * 2007-04-03 2010-07-14 Trimeris Inc NEW FORMULATIONS TO RELEASE ANTIVIRAL PEPTIDE THERAPEUTICS
US20100290982A1 (en) * 2007-04-13 2010-11-18 University Of North Texas Health Science Center At Fort Worth Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
EP2146694A4 (en) * 2007-04-13 2012-11-14 Univ North Texas FORMULATION FOR ACTIVE-LOADED PLGA NANOPARTICLES FOR TARGETED NANO TUMOR THERAPEUTICS
WO2008140026A1 (ja) 2007-05-11 2008-11-20 Bizen Chemical Co., Ltd. 新規のロイコトリエン受容体アンタゴニスト
JP5599705B2 (ja) * 2007-05-18 2014-10-01 デュレクト コーポレーション 改良されたデポー製剤
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
GB0710976D0 (en) 2007-06-07 2007-07-18 Bioalvo Am Screening method
MX2009013593A (es) 2007-06-14 2010-01-20 Biogen Idec Inc Formulaciones de anticuerpos.
WO2011084685A2 (en) 2009-12-17 2011-07-14 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
AU2008268461B2 (en) 2007-06-22 2015-04-09 Children's Medical Center Corporation Methods and uses thereof of prosaposin
AU2008269689A1 (en) 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
JP5424330B2 (ja) 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
DE102007036101A1 (de) 2007-08-01 2009-02-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue glycolidreiche Copolymere
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
DK2188313T3 (en) 2007-08-21 2017-12-11 Amgen Inc HUMAN C-FMS ANTI-BINDING PROTEINS
EP2615114B1 (en) 2007-08-23 2022-04-06 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2040075A1 (en) 2007-09-24 2009-03-25 Julius-Maximilians-Universität Würzburg Compounds and markers for surface-enhanced raman scattering
CN101874038A (zh) * 2007-09-25 2010-10-27 特里梅里斯公司 治疗性抗-hiv肽的合成方法
MY150553A (en) 2007-09-26 2014-01-30 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
WO2009044402A1 (en) * 2007-10-02 2009-04-09 Ariel - University Research And Development Company Ltd. Endocannabinoids for enhancing growth and development in infants
WO2009044774A1 (ja) 2007-10-02 2009-04-09 Chugai Seiyaku Kabushiki Kaisha インターロイキン６受容体阻害剤を有効成分とする移植片対宿主病治療剤
US20090123508A1 (en) * 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
WO2009054914A1 (en) 2007-10-19 2009-04-30 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
EP2219620B1 (en) * 2007-11-13 2017-07-19 Surmodics, Inc. Viscous terpolymers as drug delivery platform
AU2008322523B2 (en) 2007-11-16 2013-10-10 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
AU2008332276B2 (en) 2007-12-05 2014-02-27 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
RU2531521C2 (ru) 2007-12-05 2014-10-20 Чугаи Сейяку Кабусики Кайся Антитело против nr10 и его применение
AU2008347158B8 (en) * 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
WO2009075344A1 (ja) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
CN101945891A (zh) 2007-12-20 2011-01-12 爱克索马技术有限公司 治疗痛风的方法
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
JP2011514182A (ja) * 2008-02-04 2011-05-06 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 流体分離装置、システム、及び方法
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009104706A1 (ja) * 2008-02-22 2009-08-27 東レ株式会社 マイクロ粒子およびその医薬品組成物
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CN104906581A (zh) 2008-06-05 2015-09-16 国立研究开发法人国立癌症研究中心 神经浸润抑制剂
WO2010000372A2 (en) 2008-06-09 2010-01-07 Ludwig-Maximilians-Universität München New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
ES2963062T3 (es) 2008-07-23 2024-03-25 Ambrx Inc Polipéptidos G-CSF bovinos modificados y sus usos
EP2326336B1 (en) 2008-07-30 2015-05-13 Mesynthes Limited Tissue scaffolds derived from forestomach extracellular matrix
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
MX2011002418A (es) 2008-09-10 2011-04-05 Genentech Inc Metodos para inhibir la angiogenesis ocular.
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
EA019653B1 (ru) 2008-09-26 2014-05-30 Амбркс Инк. Модифицированные полипептиды эритропоэтина животных и их применение
TR201802361T4 (tr) 2008-09-26 2018-03-21 Ambrx Inc Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
WO2010042890A2 (en) 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
KR101651703B1 (ko) 2008-10-10 2016-08-26 암젠 인크 Ｆｇｆ21 돌연변이체 및 이의 용도
US9101645B2 (en) 2008-10-22 2015-08-11 Genentech, Inc. Modulation of axon degeneration
AR073997A1 (es) 2008-10-29 2010-12-15 Wyeth Corp Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US8722052B2 (en) 2008-11-17 2014-05-13 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Vaccinia virus protein A46 peptide and use thereof
WO2010062383A2 (en) 2008-11-26 2010-06-03 Amgen Inc. Stabilized receptor polypeptides and uses thereof
US20120087870A1 (en) 2008-12-19 2012-04-12 Hentges Francois Novel caviidae allergens and uses thereof
EP2367564A1 (en) 2008-12-22 2011-09-28 Universität Regensburg Norrin in the treatment of diseases associated with an increased tgf-beta activity
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
US8951546B2 (en) 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US20100158978A1 (en) * 2008-12-23 2010-06-24 Peter Markland Bioactive spray coating compositions and methods of making and uses thereof
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US9415197B2 (en) 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
EP2390261A4 (en) 2009-01-20 2012-11-14 Hanall Biopharma Co Ltd MODIFIED HUMAN THROMBOPOIETIN POLYPEPTIDE FRAGMENT AND METHOD FOR THE PRODUCTION THEREOF
CA2750003A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
WO2010085608A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
EP2396035A4 (en) 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
AU2010212851B2 (en) 2009-02-13 2012-12-13 Novartis Ag Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof
TW201031436A (en) * 2009-02-16 2010-09-01 Univ Nat Taiwan Pharmaceutical composition for inhalation delivery and fabrication method thereof
US20120114757A1 (en) 2009-02-18 2012-05-10 Bayer Pharma Aktiengesellschaft Particles comprising drospirenone encapsulated in a polymer
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
PT3248610T (pt) 2009-05-05 2024-02-01 Amgen Inc Mutantes fgf21 e suas utilizações
EP2260857A1 (en) 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
IN2012DN00352A (forum.php) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
CA2764835A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
WO2011010131A1 (en) 2009-07-21 2011-01-27 Astrazeneca Ab Compositions comprising an oxoisoquinoline methylbenzamide and a polymer
WO2011010132A1 (en) 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
AU2010278067B2 (en) 2009-07-31 2016-10-27 Shin Maeda Cancer metastasis inhibitor
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
EP2305810A1 (en) 2009-10-02 2011-04-06 Technische Universität München miRNAs in the treatment of fibrosis
EP2308478A1 (en) 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Delivery system for sustained release of a calcium-channel blocking agent
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011046457A1 (en) 2009-10-16 2011-04-21 Auckland Uniservices Limited Anti-neoplastic uses of artemin antagonists
EP2492281B1 (en) 2009-10-19 2018-04-11 HanAll Biopharma Co., Ltd. Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US20120328609A1 (en) 2009-10-22 2012-12-27 Genentech, Inc. Modulation of Axon Degeneration
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
KR20240007725A (ko) 2009-11-02 2024-01-16 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료학적 뉴클레아제 조성물 및 방법
EP2498803A4 (en) 2009-11-13 2013-05-15 Puget Sound Blood Ct FACTOR VIII CELL EPITOPARIANTS WITH REDUCED IMMUNOGENITY
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
WO2011066260A2 (en) 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
WO2011069010A2 (en) 2009-12-02 2011-06-09 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
KR20120113265A (ko) 2010-01-15 2012-10-12 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 골 치료를 촉진시키기 위한 바나듐 화합물의 용도
US20130053438A1 (en) 2010-01-19 2013-02-28 Universitat Innsbruck Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
WO2011094430A2 (en) 2010-01-27 2011-08-04 Children's Medical Center Corporation Pro-angiogenic fragments of prominin-1 and uses thereof
WO2011092242A1 (en) 2010-01-28 2011-08-04 Novo Nordisk Health Care Ag Factor vii fusion polypeptides
WO2011099007A1 (en) 2010-02-10 2011-08-18 Nayacure Therapeutics Ltd. Pharmaceutical compositions and methods for the treatment and prevention of cancer
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
WO2011112906A2 (en) 2010-03-12 2011-09-15 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
JPWO2011118804A1 (ja) 2010-03-26 2013-07-04 国立大学法人徳島大学 新規抗ｃｄ９８抗体とその用途
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
WO2011131626A1 (en) 2010-04-19 2011-10-27 Medizinische Universität Innsbruck Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
WO2011133224A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Organic compounds
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
WO2011138457A1 (en) 2010-05-07 2011-11-10 Technische Universität Graz Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
WO2011146938A1 (en) 2010-05-21 2011-11-24 NanoOncology, Inc. Reagents and methods for treating cancer
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
WO2011149051A1 (ja) 2010-05-28 2011-12-01 中外製薬株式会社 抗腫瘍t細胞応答増強剤
WO2011156594A2 (en) 2010-06-09 2011-12-15 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
KR101731008B1 (ko) 2010-06-16 2017-04-27 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
CA2802635A1 (en) 2010-06-18 2011-12-22 Xiberscience Gmbh Peptides as active agents to stabilize biologic barriers
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
US9211175B2 (en) 2010-07-08 2015-12-15 Covidien Lp Self-detachable medical devices
AU2011277983C1 (en) 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
FR2962646B1 (fr) 2010-07-16 2012-06-22 Sofradim Production Prothese avec element radio-opaque
UY33517A (es) 2010-07-19 2012-02-29 Astrazeneca Ab Depósito farmacéutico para 5-fluoro-2-[[(1S)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1H-pirazol-3-il)amino]piridin-3-carbonitrilo?.
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MX346786B (es) 2010-08-17 2017-03-31 Ambrx Inc Polipeptidos de relaxina modificados y sus usos.
WO2012030822A1 (en) 2010-08-30 2012-03-08 Surmodics Pharmaceuticals, Inc. Process for reducing moisture in a biodegradable implant device
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
KR101886890B1 (ko) 2010-09-28 2018-08-08 세키스이가가쿠 고교가부시키가이샤 항인간 ｃｃｒ７ 항체, 하이브리도마, 핵산, 벡터, 세포, 의약 조성물 및 항체 고정화 담체
US20120082647A1 (en) 2010-10-01 2012-04-05 Baker Darren P Interferon-beta for use as monotherapy or in combination with other cancer therapies
US9572907B2 (en) 2010-10-01 2017-02-21 Covidien Lp Implantable polymeric films
US8920867B2 (en) 2010-10-19 2014-12-30 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
US8632839B2 (en) 2010-10-19 2014-01-21 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
US9861590B2 (en) 2010-10-19 2018-01-09 Covidien Lp Self-supporting films for delivery of therapeutic agents
CA2816021A1 (en) 2010-10-25 2012-05-10 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
JP6066912B2 (ja) 2010-10-27 2017-01-25 アムジエン・インコーポレーテツド Ｄｋｋ１抗体およびその使用方法
BR112013010911A2 (pt) 2010-11-01 2017-05-02 Peptimed Inc composições de um sistema à base de peptídeo para direcionamento para céllas específicas
SI2644698T1 (en) 2010-11-17 2018-05-31 Chugai Seiyaku Kabushiki Kaisha MULTISPECIFIC ANTIGEN-TUBULAR MOLECULAR, WITH AN ALTERNATIVE FUNCTION TO THE FACTOR OF BLOOD VIOLATION VIII
GB201019467D0 (en) 2010-11-17 2010-12-29 Biotecnol Sa Therapeutic agent
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
EP2643019B1 (en) 2010-11-24 2019-01-02 Lexicon Pharmaceuticals, Inc. Antibodies to notum pectinacetylesterase
DK2647707T3 (en) 2010-11-30 2018-11-19 Chugai Pharmaceutical Co Ltd CYTOTOXICITY-INducing THERAPEUTIC AGENT
US8754037B2 (en) 2010-12-23 2014-06-17 Hanall Biopharma Co., Ltd. Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US9144634B2 (en) 2011-01-14 2015-09-29 Covidien Lp Medical device with intrapore films
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
EP2667715B1 (en) 2011-01-27 2017-07-19 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
CA2828000A1 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
AU2012225248A1 (en) 2011-03-10 2013-09-19 Genentech, Inc. Treatment of disorders with altered vascular barrier function
EP2694102A4 (en) 2011-04-04 2015-03-04 Univ Iowa Res Found PROCESS FOR IMPROVED VACCINE IMMUNOGENICITY
EP2694552B1 (en) 2011-04-07 2017-10-11 Amgen Inc. Novel egfr binding proteins
WO2012138919A2 (en) 2011-04-08 2012-10-11 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
KR101539313B1 (ko) 2011-04-25 2015-07-24 산동 루예 파마슈티칼 컴파니 리미티드 리스페리돈의 서방성 미소구체 조성물
DK2704737T3 (en) 2011-04-29 2018-04-23 Univ Washington THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
MX362218B (es) 2011-05-04 2019-01-09 Balance Therapeutics Inc Derivados de pentilentetrazol.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140189893A1 (en) 2011-05-10 2014-07-03 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta klotho
CA2835628C (en) 2011-05-11 2023-01-03 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2012174064A1 (en) 2011-06-14 2012-12-20 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US20140227265A1 (en) 2011-06-17 2014-08-14 Amgen Inc. Method of treating or ameliorating metabolic disorders using clec-2
FR2977790B1 (fr) 2011-07-13 2013-07-19 Sofradim Production Prothese pour hernie ombilicale
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US8579924B2 (en) 2011-07-26 2013-11-12 Covidien Lp Implantable devices including a mesh and a pivotable film
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
WO2013025479A1 (en) 2011-08-16 2013-02-21 Emory University Jaml specific binding agents, antibodies, and uses related thereto
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
CA2843369A1 (en) 2011-08-16 2013-02-21 Evotec (Munchen) Gmbh Markers for susceptibility to an inhibitor of an src-family kinase
ES2664224T3 (es) 2011-08-19 2018-04-18 Children's Medical Center Corporation Proteína de unión a VEGF para el bloqueo de la angiogénesis
US9782957B2 (en) 2011-08-24 2017-10-10 Covidien Lp Medical device films
CA2845357A1 (en) 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
JO3625B1 (ar) 2011-09-22 2020-08-27 Amgen Inc بروتينات رابطة للأنتيجين cd27l
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
JP6352634B2 (ja) 2011-09-30 2018-07-04 中外製薬株式会社 標的抗原に対する免疫応答を誘導する抗原結合分子
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013056255A1 (en) 2011-10-14 2013-04-18 The Board Of Trustees Of The University Of Illinois Methods and compositions for inhibiting tumor cell proliferation
US8906860B2 (en) 2011-10-14 2014-12-09 The Board Of Trustees Of The University Of Illinois Methods and compositions inhibiting tumor cell proliferation
AU2012325341B2 (en) 2011-10-19 2017-01-05 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US9005308B2 (en) 2011-10-25 2015-04-14 Covidien Lp Implantable film/mesh composite for passage of tissue therebetween
US9179994B2 (en) 2011-10-25 2015-11-10 Covidien Lp Implantable film/mesh composite
US8932621B2 (en) 2011-10-25 2015-01-13 Covidien Lp Implantable film/mesh composite
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
SG11201402365RA (en) 2011-11-16 2014-06-27 Amgen Inc Methods of treating epidermal growth factor deletion mutant viii related disorders
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
EP2944628B1 (en) 2011-11-30 2017-01-04 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CN107898790B (zh) 2011-11-30 2024-06-21 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
EP2785178B1 (en) 2011-12-01 2019-05-01 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
MX368200B (es) 2011-12-08 2019-09-24 Amgen Inc Proteinas de union al antigeno lecitin colesterol aciltransferasas humanas agonistas y su uso en terapia.
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
EA201491231A8 (ru) 2011-12-19 2015-01-30 Амген Инк. Варианты полипептидов рецептора активина и их применение
WO2013096868A2 (en) 2011-12-22 2013-06-27 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
JP2015504674A (ja) 2012-01-11 2015-02-16 アリゾナ ボード オブ リージェンツ ア ボディ コーポレート オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ， Ａ Ｂｏｄｙ Ｃｏｒｐｏｒａｔｅ Ｏｆ Ｔｈｅ Ｓｔａｔｅ Ｏｆ Ａｒｉｚｏｎａ Ａｃｔｉｎｇ Ｆｏｒ Ａｎｄ Ｏｎ Ｂｅｈａｌｆ Ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 神経疾患タンパク質の二重特異性抗体フラグメントおよび使用方法
JP2015506373A (ja) 2012-01-26 2015-03-02 アムジエン・インコーポレーテツド 成長分化因子１５（ｇｄｆ−１５）ポリペプチド
EP2626066A1 (en) 2012-02-10 2013-08-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
CN104271772A (zh) 2012-03-29 2015-01-07 科罗拉多州立大学董事会,公司实体 点击核酸
US10206769B2 (en) 2012-03-30 2019-02-19 Covidien Lp Implantable devices including a film providing folding characteristics
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
IN2014DN08562A (forum.php) 2012-04-14 2015-05-22 Intra Cellular Therapies Inc
JP6286757B2 (ja) 2012-04-23 2018-03-07 ジーンフロンティア株式会社 抗ヒトｃｄ６９抗体、及びその医薬用途
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
FR2992662B1 (fr) 2012-06-28 2014-08-08 Sofradim Production Tricot avec picots
FR2992547B1 (fr) 2012-06-29 2015-04-24 Sofradim Production Prothese pour hernie
EP2866821B1 (en) 2012-07-02 2018-11-14 Medizinische Universität Wien Complement split product c4d for the treatment of inflammatory conditions
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
EP4406950A3 (en) 2012-07-25 2025-04-23 Bausch + Lomb Ireland Limited Lfa-1 inhibitor and polymorph thereof
DE102013011399A1 (de) 2012-07-31 2014-02-06 Amw Gmbh Implantat mit Risperidon
EP2695950A1 (en) 2012-08-10 2014-02-12 Blackfield AG Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
US9119858B2 (en) 2012-08-21 2015-09-01 Genesys Research Institute, Inc. Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
CA2888193A1 (en) 2012-10-17 2014-04-24 Eyal Breitbart Treatment methods using adenovirus
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
AU2013342779B2 (en) 2012-11-09 2019-09-26 Genefrontier Corporation Anti-ADAM28 antibody for treating cancer
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014083178A1 (en) 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Identification of patients in need of pd-l1 inhibitor cotherapy
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
JP6326066B2 (ja) 2012-12-20 2018-05-16 メディミューン，エルエルシー 凝集プロファイルが改善されている液状抗体製剤
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
KR20150136061A (ko) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 대상에 항-액티빈-a 화합물의 투여
ES2959258T3 (es) 2013-02-07 2024-02-22 Childrens Medical Center Antígenos proteicos que proporcionan protección contra la colonización y/o la enfermedad neumocócicas
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2903769A1 (en) 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
US20140271629A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
PL2968320T3 (pl) 2013-03-15 2021-05-17 Intra-Cellular Therapies, Inc. Związki organiczne
EP2968480B1 (en) 2013-03-15 2020-10-14 Amgen Inc. Treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
EP2970483A2 (en) 2013-03-15 2016-01-20 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2014140358A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
JP6283408B2 (ja) 2013-03-15 2018-02-21 アムジェン インコーポレイテッド ヒトｐａｃ１抗体
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2983468A4 (en) 2013-03-15 2016-09-07 Durect Corp COMPOSITIONS WITH RHEOLOGY MODIFIER TO REDUCE RESOLUTION VARIABILITY
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
ES2716384T3 (es) * 2013-04-18 2019-06-12 Shandong luye pharmaceutical co ltd Composición farmacéutica de microesferas de liberación sostenida de goserelina
WO2014187881A1 (en) 2013-05-21 2014-11-27 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
CN112168953A (zh) 2013-05-22 2021-01-05 上海泽生科技开发股份有限公司 缓释纽兰格林治疗心力衰竭
US20160130585A1 (en) 2013-05-28 2016-05-12 The Johns Hopkins University Aptamers for the treatment of sickle cell disease
JP6243521B2 (ja) 2013-05-30 2017-12-06 キニクサ ファーマシューティカルズ， リミテッド オンコスタチンｍ受容体抗原結合タンパク質
EP2810648A1 (en) 2013-06-04 2014-12-10 Daniel Rauh Targeting domain-domain interaction for the identification of kinase modulators
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
CA2918787A1 (en) 2013-06-13 2014-12-18 George Tachas Combination therapy
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
EP2835135A3 (en) 2013-06-19 2015-06-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Means and methods for treating pseudomonas infection
WO2014209384A1 (en) 2013-06-28 2014-12-31 Amgen Inc. Methods for treating homozygous familial hypercholesterolema
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
DK3027642T3 (da) 2013-07-31 2020-11-02 Amgen Inc Vækstdifferentieringsfaktor 15 (gdf-15)-konstruktioner
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
CA2923835C (en) 2013-09-11 2022-11-29 The Administrators Of The Tulane Educational Fund Novel anthranilic amides and the use thereof
CA2924109A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
CN113564254A (zh) 2013-09-16 2021-10-29 分子医学研究中心责任有限公司 用于骨髓恶性肿瘤诊断的突变钙网蛋白
GB201316738D0 (en) 2013-09-20 2013-11-06 Rainbow Medical Engineering Ltd Implantable Medical Devices
EP3047857A4 (en) 2013-09-20 2017-08-09 Chugai Seiyaku Kabushiki Kaisha Treatment for hemorrhagic diseases by anti-protein-c antibody
EP3049521B1 (en) 2013-09-25 2019-03-06 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
US20150104392A1 (en) 2013-10-04 2015-04-16 Aptose Biosciences Inc. Compositions, biomarkers and their use in the treatment of cancer
JP6661531B2 (ja) 2013-10-10 2020-03-11 シナジー ファーマシューティカルズ インコーポレイテッド オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
ES2741308T3 (es) 2013-10-15 2020-02-10 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos
HUE067047T2 (hu) 2013-10-15 2024-09-28 Genefrontier Corp Humán antitest aggrekanáz típusú ADAMTS specieszek ellen aggrekanázzal kapcsolatos betegségek terápiájára
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
WO2015057908A1 (en) 2013-10-18 2015-04-23 Novartis Ag Methods of treating diabetes and related disorders
ES2724932T3 (es) 2013-10-30 2019-09-17 Univ Western Australia Péptidos neuroprotectores
DK3063275T3 (da) 2013-10-31 2019-11-25 Resolve Therapeutics Llc Terapeutiske nuklease-albumin-fusioner og fremgangsmåder
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
MX395458B (es) 2013-12-03 2025-03-25 Intra Cellular Therapies Inc Metodos novedosos
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
US10532083B2 (en) 2014-02-13 2020-01-14 Technische Universität München Methods for inducing differentiation or conversion of white adipocytes and/or preadipocytes to brown adipocites using FGF8
WO2015127134A2 (en) 2014-02-20 2015-08-27 Allergan, Inc. Complement component c5 antibodies
CA2939586A1 (en) 2014-02-27 2015-09-03 Allergan, Inc. Complement factor bb antibodies
CA2941716A1 (en) 2014-03-07 2015-09-11 The Johns Hopkins University Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
CN111620830A (zh) 2014-03-14 2020-09-04 北卡罗来纳大学教堂山分校 用于抑制雄性生育力的小分子
US12427173B2 (en) 2014-03-31 2025-09-30 Biomed Valley Discoveries, Inc. Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
KR20170012209A (ko) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
KR20170012210A (ko) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US10507227B2 (en) 2014-04-15 2019-12-17 The Hospital For Sick Children Cationic antimicrobial peptides
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
US20170073690A1 (en) 2014-05-15 2017-03-16 CEMM - Forschungzentrum Fuer Molekulare Medizin GMBH Antagonists of slc38a9 and their use in therapy
WO2015179415A1 (en) 2014-05-19 2015-11-26 Novartis Ag Methods of treating anorexia
US11357748B2 (en) 2014-05-30 2022-06-14 The Johns Hopkins University Methods for treating mendelian disorders of the epigenetic machinery
EP3154584B1 (en) 2014-06-03 2021-08-04 XBiotech Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
LT3845245T (lt) 2014-06-09 2025-09-25 Ultragenyx Pharmaceutical Inc. Veiksminga ir efektyvi serumo fosfatų kontrolė, skirta optimalaus kaulų formavimosi užtikrinimui
CA2952231A1 (en) 2014-06-13 2015-12-17 Santa Maria Biotherapeutics, Inc. Formulated receptor polypeptides and related methods
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
US10166304B2 (en) 2014-07-11 2019-01-01 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
EP2977758A1 (en) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
EP3174901B1 (en) 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Optimized cross-species specific bispecific single chain antibody constructs
EP3180018B1 (en) 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
EP4491184A3 (en) 2014-08-22 2025-03-26 Auckland Uniservices Limited Channel modulators
JP2017530948A (ja) 2014-08-27 2017-10-19 ペプティメド， インコーポレイテッド 抗腫瘍組成物および方法
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CA2962451C (en) 2014-10-21 2023-01-17 Sciclone Pharmaceuticals, Inc. Treatment of cancer with immune stimulators
EP3909596A1 (en) 2014-10-24 2021-11-17 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
WO2016079321A1 (en) 2014-11-20 2016-05-26 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Antagonists of setdb2 for use in the therapy of infectious diseases
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
CN107835820B (zh) 2015-01-26 2021-10-15 芝加哥大学 识别癌症特异性IL13Rα2的CAR T细胞
EP3250609A4 (en) 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
EP3262064A1 (en) 2015-02-23 2018-01-03 Seagull Therapeutics SAS Non-natural semaphorins 3 and their medical use
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
MX2017012966A (es) 2015-04-10 2018-06-06 Amgen Inc Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
ES2945313T3 (es) 2015-04-17 2023-06-30 Amgen Res Munich Gmbh Construcciones de anticuerpos biespecificos para CDH3 y CD3
EP3294072A4 (en) * 2015-05-15 2019-03-13 The Johns Hopkins University NOVEL PRENATAL FOOD SUPPLEMENT WITH FLUORIDE
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
EP3319613B1 (en) 2015-07-07 2023-02-22 The Research Foundation for The State University of New York Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
ES2546566B2 (es) * 2015-07-23 2016-09-14 Universidade De Santiago De Compostela Sistema para la administración de sustancias biológicamente activas preparado por técnicas de espumado empleando gases comprimidos o fluidos supercríticos
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
CA2994162A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Glutamine antagonists for the treatment of cognitive deficits
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
LT3328827T (lt) 2015-07-31 2023-10-10 The Johns Hopkins University Glutamino analogų provaistai
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
CN108348492B (zh) 2015-07-31 2021-09-28 约翰霍普金斯大学 使用谷氨酰胺类似物的用于癌症和免疫疗法的方法
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
AU2016332062A1 (en) 2015-10-01 2018-04-26 Amgen Inc. Treatment of bile acid disorders
EP3370763B1 (en) 2015-11-03 2024-04-10 Regents of the University of Minnesota Cd200 inhibitors and methods of use thereof
EP3371222A1 (en) 2015-11-03 2018-09-12 GlycoMimetics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
WO2017079272A2 (en) 2015-11-03 2017-05-11 Ambrx, Inc. Anti-cd3-folate conjugates and their uses
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
US11338022B2 (en) 2015-12-18 2022-05-24 Talengen International Limited Method for preventing and treating angiocardiopathy
EP3394104A2 (en) 2015-12-23 2018-10-31 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
HUE064667T2 (hu) 2016-01-26 2024-04-28 Intra Cellular Therapies Inc Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra
ES2905361T3 (es) 2016-02-03 2022-04-08 Amgen Res Munich Gmbh Construcciones de anticuerpo de acoplamiento a linfocitos T biespecíficas para BCMA y CD3
IL260920B (en) 2016-02-03 2022-09-01 Amgen Res Munich Gmbh Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof
US10098909B2 (en) 2016-02-05 2018-10-16 University Of South Florida Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
EP3414573B1 (en) 2016-02-10 2023-11-08 Rutgers, the State University of New Jersey Novel anti-lam antibodies
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
CN109069640B (zh) 2016-03-14 2023-10-03 中外制药株式会社 用于癌症治疗的诱导细胞损伤的治疗药物
SI3407889T1 (sl) 2016-03-25 2021-09-30 Intra-Cellular Therapies, Inc. Organske spojine in njihova uporaba v zdravljenju ali preprečevanju motenj centralnega živčnega sistema
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
JP7422480B2 (ja) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
MA45554A (fr) 2016-07-01 2019-05-08 Resolve Therapeutics Llc Fusions de binucléase optimisées.
CA3028450A1 (en) 2016-07-06 2018-01-11 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
AU2017310412A1 (en) 2016-08-08 2019-02-21 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
SG11201901961SA (en) 2016-09-06 2019-04-29 Chugai Pharmaceutical Co Ltd Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US11292783B2 (en) 2016-09-16 2022-04-05 Research Triangle Institute Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists
CN110072518B (zh) 2016-10-12 2021-10-26 细胞内治疗公司 无定形固体分散体
ES3030503T3 (en) 2016-10-19 2025-06-30 Scripps Research Inst Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
JP7531080B2 (ja) 2016-12-15 2024-08-09 タレンゲン インターナショナル リミテッド 骨粗鬆症を予防及び治療するための薬物およびその用途
TW201822797A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學研究院有限公司 一種預防和治療腎纖維化的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
CN110114081A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种改善心脏病变的方法
WO2018107708A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种促进胰岛素受体底物-2表达的方法
TW202123963A (zh) 2016-12-15 2021-07-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
TW201822790A (zh) 2016-12-15 2018-07-01 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療皮膚纖維化的方法
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
WO2018128454A1 (ko) 2017-01-06 2018-07-12 에이비엘바이오 주식회사 항 α-SYN 항체 및 그 용도
CN110494445B (zh) 2017-01-06 2023-10-20 Abl生物公司 抗α-SYN抗体及其用途
WO2018129470A1 (en) 2017-01-09 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Reversing deficient hedgehog signaling restores deficient skeletal regeneration
US10603358B2 (en) 2017-01-10 2020-03-31 Nodus Therapeutics Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
WO2018130554A1 (en) 2017-01-11 2018-07-19 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
MY193457A (en) 2017-02-08 2022-10-14 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
WO2018160791A1 (en) 2017-03-03 2018-09-07 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
US10421968B2 (en) 2017-03-15 2019-09-24 Versitech Limited Amphiphilic dendrimers complexed with siRNA for treatment of cancer
CN110430879B (zh) 2017-03-24 2023-04-21 细胞内治疗公司 新组合物和方法
EP3615937A4 (en) 2017-04-25 2021-08-11 Prothera Biologics, Inc. METHOD OF QUANTIFYING INTER-ALPHA INHIBITOR PROTEINS
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
SG11201910183SA (en) 2017-05-04 2019-11-28 Helsingin Yliopisto C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof
TWI868050B (zh) 2017-05-05 2025-01-01 美商安進公司 用於改良儲存及投與之包含雙特異性抗體構築體之醫藥組成物
ES3035044T3 (en) 2017-05-12 2025-08-27 Max Planck Gesellschaft Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
DK3643321T3 (da) 2017-06-19 2025-08-18 Talengen Int Ltd Plasminogen til anvendelse i behandling af parkinsons og alzheimers sygdom
US20190062428A1 (en) 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
CN110831969B (zh) 2017-06-20 2024-06-21 安进公司 使用抑胃肽受体（gipr）结合蛋白与glp-1激动剂的组合治疗或改善代谢障碍的方法
EP3642238A1 (en) 2017-06-21 2020-04-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
AU2018301393B2 (en) 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
JP2020528054A (ja) 2017-07-19 2020-09-17 オークランド ユニサービシズ リミテッド サイトカインモジュレーション
WO2019023063A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
MX2020000968A (es) 2017-07-26 2020-09-28 Intra Cellular Therapies Inc Compuestos organicos.
US11077199B2 (en) 2017-08-09 2021-08-03 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
US11485781B2 (en) 2017-08-17 2022-11-01 Massachusetts Institute Of Technology Multiple specificity binders of CXC chemokines
JP7374091B2 (ja) 2017-08-22 2023-11-06 サナバイオ， エルエルシー 可溶性インターフェロン受容体およびその使用
CN111148533A (zh) 2017-09-19 2020-05-12 麻省理工学院 用于嵌合抗原受体t细胞疗法的组合物及其用途
EA202090581A1 (ru) 2017-10-04 2020-08-31 Амген Инк. Продукты слияния транстиретина и иммуноглобулина
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2019089365A1 (en) 2017-10-30 2019-05-09 Enterin Laboratories, Inc. New squalamine solid forms and methods of making the same
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
CN111315780A (zh) 2017-12-11 2020-06-19 安进公司 双特异性抗体产品的连续制造工艺
KR102263812B1 (ko) 2017-12-14 2021-06-14 에이비엘바이오 주식회사 a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도
CA3123318A1 (en) 2017-12-15 2019-06-20 Talengen International Limited Method and drug for preventing or treating osteoarthritis
EP3727447A1 (en) 2017-12-19 2020-10-28 Massachusetts Institute of Technology Antigen-adjuvant coupling reagents and methods of use
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
DK3749353T3 (da) 2018-02-09 2025-09-01 Galderma Holding SA Nemolizumab til behandling af atopisk dermatitis med moderat til svær excoriation
EP3765524A4 (en) 2018-03-14 2021-12-22 Surface Oncology, Inc. ANTIBODIES THAT BIND TO CD39 AND THEIR USES
EP3765021A4 (en) 2018-03-16 2022-03-09 Intra-Cellular Therapies, Inc. NOVEL PROCESSES
EP3768317A4 (en) 2018-03-22 2021-12-22 Surface Oncology, Inc. ANTI-IL-27 ANTIBODIES AND THEIR USES
CA3095101A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Deuterated octahydro-quinoxaline derivatives and pharmaceutical compositions thereof use in the treatment of diseases involving serotonin 5-ht2a, dopamine d1/d2 and/or serotonin reuptake transporter (sert) pathways
JP7462568B2 (ja) 2018-03-23 2024-04-05 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP2021519578A (ja) 2018-03-29 2021-08-12 ヘルシンギン ユリオピストＨｅｌｓｉｎｇｉｎ Ｙｌｉｏｐｉｓｔｏ Ｃ末端ｃｄｎｆ断片、それらを含む医薬組成物、並びにそれらの使用
US11466079B2 (en) 2018-03-30 2022-10-11 Amgen Inc. C-terminal antibody variants
PE20201350A1 (es) 2018-04-09 2020-11-30 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
CN119286871A (zh) 2018-04-19 2025-01-10 查美特制药公司 合成rig-i样受体激动剂
WO2019207051A1 (en) 2018-04-25 2019-10-31 Università Degli Studi Di Torino Medical use of combinations of non-natural semaphorins 3 and antimetabolites
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
CA3102948A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
AU2019284362A1 (en) 2018-06-11 2021-01-07 University Of Florida Research Foundation, Inc. Materials and methods for treating stress-related disorders and cancer
JP7483671B2 (ja) 2018-06-11 2024-05-15 イントラ－セルラー・セラピーズ・インコーポレイテッド 置換ヘテロ環縮合ガンマ－カルボリン類合成
JP2021526837A (ja) 2018-06-12 2021-10-11 アンジーエックス・インコーポレーテッド 抗体−オリゴヌクレオチドコンジュゲート
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
EP3833443A1 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020033926A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
JP7759805B2 (ja) 2018-08-28 2025-10-24 アンブルックス，インコーポレイテッド 抗ｃｄ３抗体葉酸生物複合体およびその使用
EP3843729A4 (en) 2018-08-29 2022-06-01 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
BR112021003838A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
CN112584837A (zh) 2018-08-31 2021-03-30 细胞内治疗公司 新方法
PL3849614T3 (pl) 2018-09-11 2024-04-22 Ambrx, Inc. Koniugaty polipeptydu interleukiny-2 i ich zastosowania
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
KR20210068478A (ko) 2018-09-28 2021-06-09 메사추세츠 인스티튜트 오브 테크놀로지 콜라겐-국재화된 면역조정성 분자 및 그의 방법
SG11202103275YA (en) 2018-10-11 2021-04-29 Amgen Inc Downstream processing of bispecific antibody constructs
US20220009986A1 (en) 2018-10-19 2022-01-13 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
SG11202105161YA (en) 2018-12-13 2021-06-29 Surface Oncology Inc Anti-il-27 antibodies and uses thereof
CA3121635A1 (en) 2018-12-17 2020-06-25 Intra-Cellular Therapies, Inc. Serotonin 5-ht2a receptor antagonist
AU2020204992A1 (en) 2019-01-04 2021-07-15 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
US11680105B2 (en) 2019-01-17 2023-06-20 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
US11236157B2 (en) 2019-01-28 2022-02-01 Galderma Holding SA Treatment of skin lesions and pruritus in prurigo nodularis patients
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
NZ778565A (en) 2019-02-12 2025-10-31 Ambrx Inc Compositions containing, methods and uses of antibody-tlr agonist conjugates
US12453777B2 (en) 2019-03-20 2025-10-28 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
US12357620B2 (en) 2019-03-22 2025-07-15 New York Medical College Use of rifaximin on circulating aged neutrophils in sickle cell disease
CA3133610A1 (en) 2019-03-29 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
CA3135694A1 (en) 2019-04-17 2020-10-22 Hiroshima University Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
EP3967322B1 (en) 2019-05-10 2025-03-05 Talengen International Limited Plasminogen for treating amyotrophic lateral sclerosis
WO2020241816A1 (ja) 2019-05-31 2020-12-03 国立大学法人大阪大学 新規な消化器がん治療剤およびそのスクリーニング方法
BR112021023735A2 (pt) 2019-06-05 2022-01-04 Chugai Pharmaceutical Co Ltd Molécula de ligação de sítio de clivagem de anti-corpo
US20220348658A1 (en) 2019-06-10 2022-11-03 Chugai Seiyaku Kabushiki Kaisha Anti-t cell antigen-binding molecule to be used in combination with cytokine inhibitor
CA3137494A1 (en) 2019-06-13 2020-12-17 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
US20210000822A1 (en) 2019-07-07 2021-01-07 Intra-Cellular Therapies, Inc. Novel methods
SG11202112762TA (en) 2019-07-08 2021-12-30 Amgen Inc Multispecific transthyretin immunoglobulin fusions
CN113950485A (zh) 2019-07-10 2022-01-18 中外制药株式会社 密蛋白-6结合分子及其用途
US20220281966A1 (en) 2019-07-26 2022-09-08 Amgen Inc. Anti-il13 antigen binding proteins
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
GB201910899D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Binding members
BR112022002666A2 (pt) 2019-08-13 2022-08-09 Amgen Inc Muteínas de interleucina-2 para a expansão de células t reguladoras
GB201912657D0 (en) 2019-09-03 2019-10-16 Scancell Ltd Binding members
GB201912882D0 (en) 2019-09-06 2019-10-23 Scancell Ltd Ssea-4 binding members
US11655303B2 (en) 2019-09-16 2023-05-23 Surface Oncology, Inc. Anti-CD39 antibody compositions and methods
CA3151078A1 (en) 2019-09-25 2021-04-01 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
TW202207984A (zh) 2019-10-11 2022-03-01 日商中外製藥股份有限公司 用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品
CN115279905A (zh) 2019-10-23 2022-11-01 里珍纳龙药品有限公司 合成rig-i样受体激动剂
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
US20220380487A1 (en) 2019-10-24 2022-12-01 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
CN114728927B (zh) 2019-11-19 2025-08-29 莫达戈有限公司 用于诊断、治疗和预防与α-突触核蛋白的聚集相关的疾病的化合物
US11753419B2 (en) 2019-12-11 2023-09-12 Intra-Cellular Therapies, Inc. 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
PE20221506A1 (es) 2019-12-17 2022-10-04 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia
EP3838345A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Macrocyclic peptides
EP3838912A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Retro-inverso peptides
CA3160204A1 (en) 2020-01-06 2021-07-15 Vaccinex, Inc. Anti-ccr8 antibodies and uses thereof
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
JP7641025B2 (ja) 2020-01-17 2025-03-06 タレンゲン インターナショナル リミテッド 神経損傷及び関連障害を治療するための方法
CA3167202A1 (en) 2020-02-06 2021-08-12 Jinan Li Method and drug for preventing and treating multiple sclerosis
WO2021160092A1 (zh) 2020-02-11 2021-08-19 泰伦基国际有限公司 一种治疗病毒性肺炎的方法和药物
EP4112069B1 (en) 2020-02-26 2025-08-06 Talengen International Limited Components of the plasminogen activation pathway for use in the treatment of hypertension
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
EP4117732A1 (en) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021188851A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
CN115666625A (zh) 2020-03-24 2023-01-31 泰伦基国际有限公司 一种促进错误折叠蛋白及其聚集物降解的方法和药物
CN115666612A (zh) 2020-03-24 2023-01-31 泰伦基国际有限公司 一种治疗亨廷顿病的方法和药物
TWI868333B (zh) 2020-03-24 2025-01-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療阿茲海默症的方法和藥物
CA3176934A1 (en) 2020-03-24 2021-09-30 Talengen International Limited Method and drug for treating parkinson's disease
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US20230181699A1 (en) 2020-05-11 2023-06-15 Talengen International Limited Method and drug for treating spinal muscular atrophy
WO2021248081A1 (en) 2020-06-05 2021-12-09 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Acvr1 (alk2) receptor inhibition to treat neurological diseases
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
KR102594943B1 (ko) 2020-06-19 2023-10-27 추가이 세이야쿠 가부시키가이샤 혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자
US20230355722A1 (en) 2020-06-29 2023-11-09 Resolve Therapeutics, Llc Treatment of sjogren’s syndrome with nuclease fusion proteins
IL300225A (en) 2020-07-31 2023-03-01 Chugai Pharmaceutical Co Ltd A pharmaceutical composition including chimeric receptor expressing cells
WO2022023292A2 (en) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Corona virus spike protein-targeting antibodies and use thereof
WO2022040596A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
CA3189358A1 (en) 2020-08-26 2022-03-03 Scancell Limited Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
WO2022081436A1 (en) 2020-10-15 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
TW202233680A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性之多靶向性雙特異性抗原結合分子
JP7682567B2 (ja) 2020-11-17 2025-05-26 泰▲倫▼基国▲際▼有限公司 Ｎｇｆレベルを増加させる方法及び薬剤
KR20230107635A (ko) 2020-11-17 2023-07-17 탈렌젠 인터내셔널 리미티드 Bdnf 수준의 향상을 위한 방법 및 약물
KR20230145053A (ko) 2021-01-12 2023-10-17 듀렉트 코퍼레이션 지속 방출 약물 전달 시스템 및 관련 방법
AU2022224636A1 (en) 2021-02-19 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that neutralize sars-cov-2
IL305793A (en) 2021-03-12 2023-11-01 Hoffmann La Roche A pharmaceutical preparation for the treatment or prevention of myasthenia gravis
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
US20250197525A1 (en) 2021-04-28 2025-06-19 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
CA3217180A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
AU2022270170A1 (en) 2021-05-07 2023-09-21 Surface Oncology, LLC Anti-il-27 antibodies and uses thereof
MX2023012782A (es) 2021-05-14 2024-03-25 Claris Biotherapeutics Inc Composiciones de factor de crecimiento para el tratamiento de enfermedades oculares.
AU2022336625A1 (en) 2021-09-03 2024-04-11 University Of Bern Compositions and methods for treating long qt syndrome
JPWO2023053282A1 (forum.php) 2021-09-29 2023-04-06
IL312060A (en) 2021-11-03 2024-06-01 Affimed Gmbh Bispecific CD16A binders
CA3237018A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
KR102707065B1 (ko) 2022-03-08 2024-09-19 동국제약 주식회사 코아세르베이션법을 이용하여 현탁성이 개선된 미립구의 제조방법
EP4511013A1 (en) 2022-04-19 2025-02-26 Philera New Zealand Ltd. Treatment of brain copper disorders
EP4522651A1 (en) 2022-05-12 2025-03-19 Amgen Research (Munich) GmbH Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
EP4525874A1 (en) 2022-05-18 2025-03-26 Intra-Cellular Therapies, Inc. Novel methods
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
WO2023230128A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
WO2023230116A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20250368724A1 (en) 2022-06-16 2025-12-04 Osaka University Novel therapeutic agent for inflammatory diseases and screening method thereof
AR130384A1 (es) 2022-09-02 2024-12-04 Univ Of Bern Composiciones y métodos para tratar el síndrome de qt largo
CA3266491A1 (en) 2022-09-02 2024-03-07 Chugai Pharmaceutical Co Ltd PRURIGO NODULARIS TREATMENTS
TW202421650A (zh) 2022-09-14 2024-06-01 美商安進公司 雙特異性分子穩定組成物
WO2024076995A1 (en) 2022-10-03 2024-04-11 Insigna Inc. Compositions for non-surgical prevention of boar taint and aggressive behavior
IL320158A (en) 2022-10-18 2025-06-01 Nb Health Laboratory Co Ltd Antibody, nucleic acid, cell, and pharmaceutical
WO2024094217A1 (zh) 2022-11-04 2024-05-10 泰伦基国际有限公司 一种促进病理性tdp-43蛋白降解的方法和药物
KR20250099725A (ko) 2022-11-04 2025-07-02 탈렌젠 인터내셔널 리미티드 유비퀴틴 프로테아좀 시스템 및 자가포식 리소좀 시스템에 의한 병리학적 단백질의 제거를 촉진하는 방법 및 약물
EP4630537A1 (en) 2022-12-07 2025-10-15 Fondazione Matilde Tettamanti e Menotti de Marchi Onlus Methods for generating genetically modified cytokine induced killer (cik) cells
CN115804830B (zh) * 2022-12-16 2024-08-20 浙江圣兆药物科技股份有限公司 一种缩短迟滞期的戈舍瑞林缓释植入剂
AU2023418793A1 (en) 2022-12-30 2025-06-12 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor
WO2024173901A1 (en) 2023-02-17 2024-08-22 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
WO2025006676A2 (en) 2023-06-27 2025-01-02 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
WO2025155602A1 (en) 2024-01-16 2025-07-24 Genentech, Inc. Method of treating hemophilia a
WO2025191291A1 (en) 2024-03-14 2025-09-18 Universidad Complutense De Madrid Methods for the prevention or treatment of erectile dysfunction (ed) by administering slpis (secretory leukocyte protease inhibitors)
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
JPS5324423B2 (forum.php) * 1972-04-29 1978-07-20
JPS5017525A (forum.php) * 1973-06-14 1975-02-24
JPS5749532B2 (forum.php) * 1974-03-19 1982-10-22
JPS5035158A (forum.php) * 1973-07-24 1975-04-03
JPS5726506B2 (forum.php) * 1974-03-08 1982-06-04
JPS5314072B2 (forum.php) * 1973-09-29 1978-05-15
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
NZ181036A (en) * 1975-06-12 1978-12-18 A Schally Luteinising hormone releasing hormone analogues and intermediates therefor
US4010196A (en) * 1975-06-25 1977-03-01 American Home Products Corporation Linear polyester salts
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
CA1123984A (en) * 1977-11-16 1982-05-18 Yuzi Okuzumi Block copolymers of lactide and glycolide and surgical prosthesis therefrom
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4333919A (en) * 1979-09-12 1982-06-08 Eli Lilly And Company Growth promotant controlled release formulations and method of treatment
AU534665B2 (en) * 1979-09-12 1984-02-09 Eli Lilly And Company Method
US4331652A (en) * 1979-09-12 1982-05-25 Eli Lilly And Company Controlled release parasitic formulations and method
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions

Also Published As

Publication number Publication date
DK59182A (da) 1982-08-17
AU7998682A (en) 1982-08-26
JPH0686390B2 (ja) 1994-11-02
HK107890A (en) 1990-12-28
JPS57150609A (en) 1982-09-17
AU2840789A (en) 1989-05-04
JPH0157098B2 (forum.php) 1989-12-04
FI820467L (fi) 1982-08-17
ES8307845A1 (es) 1983-08-01
GR76791B (forum.php) 1984-09-04
EP0058481B1 (en) 1986-10-01
IE52535B1 (en) 1987-12-09
HU199695B (en) 1990-03-28
AU6498886A (en) 1987-02-19
HU186904B (en) 1985-10-28
JPS6264824A (ja) 1987-03-23
NO162103B (no) 1989-07-31
AU560829B2 (en) 1987-04-16
YU44066B (en) 1990-02-28
JPH05271051A (ja) 1993-10-19
JPH05221871A (ja) 1993-08-31
EP0058481B2 (en) 2003-05-21
US4767628A (en) 1988-08-30
JPH0774143B2 (ja) 1995-08-09
YU31582A (en) 1985-04-30
ES509647A0 (es) 1983-08-01
ZA82565B (en) 1982-10-27
IE820165L (en) 1982-08-16
MY101545A (en) 1991-12-17
DE3273501D1 (en) 1986-11-06
NZ199732A (en) 1985-08-30
AU602623B2 (en) 1990-10-18
DK164845B (da) 1992-08-31
NO820433L (no) 1982-08-17
ATE22535T1 (de) 1986-10-15
PT74434A (en) 1982-03-01
CA1169090A (en) 1984-06-12
PT74434B (en) 1983-07-14
EP0058481A1 (en) 1982-08-25
US4767628B1 (forum.php) 1990-07-17
JPH031330B2 (forum.php) 1991-01-10
NO162103C (no) 1992-03-04
AU582920B2 (en) 1989-04-13
US5004602A (en) 1991-04-02

Similar Documents

Publication Publication Date Title
FI80594B (fi) Foerfarande foer framstaellning av en komposition som frigoers kontinuerligt polypeptid, poly(laktidkoglykolid)polymer och foerfarande foer dess framstaellning.
US5366734A (en) Continuous release pharmaceutical compositions
CA1100041A (en) Absorbable pharmaceutical compositions based on isomorphic copolyoxalates
FI80284B (fi) Farmaceutiskt eller veterinaert godtagbar amfipatisk blocksampolymer och dess framstaellning.
US4801739A (en) Oligomeric hydroxycarboxylic acid derivatives, their production and use
US4882168A (en) Polyesters containing alkylene oxide blocks as drug delivery systems
US4906474A (en) Bioerodible polyanhydrides for controlled drug delivery
EP0302582A1 (en) Drug delivery system and method of making the same
EP0258780A2 (en) Polyesters containing alkylene oxide blocks as drug delivery systems
US4186189A (en) Absorbable pharmaceutical compositions based on poly(alkylene oxalates)
Rothen-Weinhold et al. Analysis of the influence of polymer characteristics and core loading on the in vivo release of a somatostatin analogue
Fildes et al. The development of ‘Zoladex'history
Hutchinson et al. Pharmaceutical Department and Research Department Imperial Chemical Industries PLC, Pharmaceuticals Division Mereside, Alderley Park Macclesfield, Cheshire SK1O 4TG, UK

Legal Events

Date Code Title Description
FC Application refused

Owner name: IMPERIAL CHEMICAL INDUSTRIES PLC